These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 1283117)

  • 1. Prolonged treatment with finasteride (a 5 alpha-reductase inhibitor) does not affect bone density and metabolism.
    Matzkin H; Chen J; Weisman Y; Goldray D; Pappas F; Jaccard N; Braf Z
    Clin Endocrinol (Oxf); 1992 Nov; 37(5):432-6. PubMed ID: 1283117
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Finasteride, an inhibitor of 5 alpha-reductase, suppresses prostatic dihydrotestosterone in men with benign prostatic hyperplasia.
    McConnell JD; Wilson JD; George FW; Geller J; Pappas F; Stoner E
    J Clin Endocrinol Metab; 1992 Mar; 74(3):505-8. PubMed ID: 1371291
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effect of finasteride in men with benign prostatic hyperplasia. The Finasteride Study Group.
    Gormley GJ; Stoner E; Bruskewitz RC; Imperato-McGinley J; Walsh PC; McConnell JD; Andriole GL; Geller J; Bracken BR; Tenover JS
    N Engl J Med; 1992 Oct; 327(17):1185-91. PubMed ID: 1383816
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The clinical effects of a 5 alpha-reductase inhibitor, finasteride, on benign prostatic hyperplasia. The Finasteride Study Group.
    Stoner E
    J Urol; 1992 May; 147(5):1298-302. PubMed ID: 1373779
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Finasteride (MK-906) in the treatment of benign prostatic hyperplasia. The Finasteride Study Group.
    Prostate; 1993; 22(4):291-9. PubMed ID: 7684524
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differential effect of finasteride on the tissue androgen concentrations in benign prostatic hyperplasia.
    Habib FK; Ross M; Tate R; Chisholm GD
    Clin Endocrinol (Oxf); 1997 Feb; 46(2):137-44. PubMed ID: 9135694
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The clinical development of a 5 alpha-reductase inhibitor, finasteride.
    Stoner E
    J Steroid Biochem Mol Biol; 1990 Nov; 37(3):375-8. PubMed ID: 1701660
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term urodynamic effects of finasteride in benign prostatic hyperplasia: a pilot study.
    Kirby RS; Vale J; Bryan J; Holmes K; Webb JA
    Eur Urol; 1993; 24(1):20-6. PubMed ID: 7689971
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Scandinavian clinical study of finasteride in the treatment of benign prostatic hyperplasia.
    Beisland HO; Binkowitz B; Brekkan E; Ekman P; Kontturi M; Lehtonen T; Lundmo P; Pappas F; Round E; Shapiro D
    Eur Urol; 1992; 22(4):271-7. PubMed ID: 1283370
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Finasteride in the treatment of benign prostatic hyperplasia. A urodynamic evaluation.
    Kirby RS; Bryan J; Eardley I; Christmas TJ; Liu S; Holmes SA; Vale JA; Shanmuganathan K; Webb JA
    Br J Urol; 1992 Jul; 70(1):65-72. PubMed ID: 1379107
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 5 alpha-metabolism in finasteride-treated subjects and male pseudohermaphrodites with inherited 5 alpha-reductase deficiency. A review.
    Imperato-McGinley J
    Eur Urol; 1991; 20 Suppl 1():78-81. PubMed ID: 1722167
    [TBL] [Abstract][Full Text] [Related]  

  • 12. C19 and C21 5 beta/5 alpha metabolite ratios in subjects treated with the 5 alpha-reductase inhibitor finasteride: comparison of male pseudohermaphrodites with inherited 5 alpha-reductase deficiency.
    Imperato-McGinley J; Shackleton C; Orlic S; Stoner E
    J Clin Endocrinol Metab; 1990 Mar; 70(3):777-82. PubMed ID: 1689740
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hormonal effects of a 5 alpha-reductase inhibitor (finasteride) on hormonal levels in normal men and in patients with benign prostatic hyperplasia.
    Vermeulen A; Giagulli VA; De Schepper P; Buntinx A
    Eur Urol; 1991; 20 Suppl 1():82-6. PubMed ID: 1722168
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The long-term effect of specific type II 5alpha-reductase inhibition with finasteride on bone mineral density in men: results of a 4-year placebo controlled trial.
    Matsumoto AM; Tenover L; McClung M; Mobley D; Geller J; Sullivan M; Grayhack J; Wessells H; Kadmon D; Flanagan M; Zhang GK; Schmidt J; Taylor AM; Lee M; Waldstreicher J;
    J Urol; 2002 May; 167(5):2105-8. PubMed ID: 11956450
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effect of 5alpha-reductase inhibition with finasteride and dutasteride on bone mineral density in older men with benign prostatic hyperplasia.
    Mačukat IR; Spanjol J; Orlič ZC; Butorac MZ; Marinovič M; Ćupič DF
    Coll Antropol; 2014 Sep; 38(3):835-9. PubMed ID: 25420363
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Finasteride for benign prostatic hyperplasia.
    Hasinski S; Miller JL; Rose LI
    Am Fam Physician; 1992 Nov; 46(5):1511-4. PubMed ID: 1279965
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Finasteride therapy does not alter bone turnover in men with benign prostatic hyperplasia--a Clinical Research Center study.
    Tollin SR; Rosen HN; Zurowski K; Saltzman B; Zeind AJ; Berg S; Greenspan SL
    J Clin Endocrinol Metab; 1996 Mar; 81(3):1031-4. PubMed ID: 8772571
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of finasteride in men with benign prostatic hyperplasia.
    Walsh PC
    J Urol; 1993 Apr; 149(4):932-3. PubMed ID: 7681121
    [No Abstract]   [Full Text] [Related]  

  • 19. [Effect of dutasteride on reduction of plasma DHT following finasteride therapy in patients with benign prostatic hyperplasia].
    Botto H; Lan O; Poulain JE; Comenducci A
    Prog Urol; 2005 Dec; 15(6):1090-5. PubMed ID: 16429658
    [TBL] [Abstract][Full Text] [Related]  

  • 20. One-year experience in the treatment of benign prostatic hyperplasia with finasteride. The MK-906 (Finasteride) Study Group.
    J Androl; 1991; 12(6):372-5. PubMed ID: 1722792
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.